Head-to-head evidence
AND017 vs Enarodustat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline
AND017
Developed by Kind Pharmaceuticals
NCT05265325 · Phase 2 · completed
The study was randomized, triple-blind, and active-controlled, with 175 participants assigned to AND017 or standard erythropoiesis-stimulating therapy. However, the registry does not report whether the primary endpoints—adverse-event incidence and mean hemoglobin change at Week 6—were met, so the findings cannot be judged as demonstrating a positive effect.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: October 2026 · NCT07494409 (registry estimate)
Enarodustat
Marketed by Akros Pharma and partners
NCT04027517 · Phase 3 · completed
The trial was randomized and actively controlled with 172 participants, but it was open-label and used hemoglobin, a laboratory surrogate, as its primary endpoint. Because no primary endpoint results or statistical comparison are available, the study provides limited evidence rather than demonstrating a positive or negative treatment effect.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: June 2027 · NCT07079579 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AND017's landscape · Enarodustat's landscape